Kendall Stevinson

Statistics

Publications

Citations

141

H-Index

Active since

2017

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (Germany)

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Hospital Clínic de Barcelona

Elbe Kliniken Stade-Buxtehude

Kendall Stevinson is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and metastatic melanoma treatment.

Publications per year

2017–2021

Publications

Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States

Jingshu Wang, Bartosz Chmielowski, James M. Pellissier et al. · Journal of Managed Care & Specialty Pharmacy · 2017 · 63 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices

C. Lance Cowey, Frank Xiaoqing Liu, Jenny Black-Shinn et al. · Journal of Immunotherapy · 2017 · 31 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)

Grant A. McArthur, Peter Mohr, Paolo A. Ascierto et al. · The Oncologist · 2017 · 18 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Real‐world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab

Peter G. Mohr, Paolo A. Ascierto, Ana Arance et al. · Journal of the European Academy of Dermatology and Venereology · 2017 · 16 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in <i>KRAS</i> p.G12C mutated non-small cell lung cancer (NSCLC).

Alexander I. Spira, Frederick H. Wilson, Geoffrey I. Shapiro et al. · Journal of Clinical Oncology · 2021 · 13 citations

Medicine, Oncology, Pharmacotherapy +14

1–5 of 5